Mallinckrodt plc (MNK) has 7,010,784 shares of shorts outstanding as on August 15, 2016, with 3 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 8,962,307 shares. The stock has a decent trading volume of 2,170,839 shares daily. The marginal decrease in the short positions is by -21.8%, which amounts to -1,951,523 shares. Short positions are 6.5% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.
Mallinckrodt plc (NYSE:MNK): The stock opened at $84.54 on Wednesday but the bulls could not build on the opening and the stock topped out at $85.83 for the day. The stock traded down to $78.20 during the day, due to lack of any buying support eventually closed down at $79.14 with a loss of -4.72% for the day. The stock had closed at $83.06 on the previous day. The total traded volume was 5,319,050 shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the CFO of Mallinckrodt Plc, Harbaugh Matthew K had purchased shares worth of $29,685 in a transaction dated on May 10, 2016. A total of 500 shares were purchased at a price of $59.37 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.